-
Review Article
Neonatal and maternal outcomes of mRNA versus Non-mRNA COVID-19 vaccines in pregnant patients: a systematic review and meta-analysis
- Juliana Almeida Oliveira
, - Eloisa Gonçalves da Silva ,
- Ayse Filiz Gokmen Karasu ,
- Anelise Maria Nicolau Silva ,
- Chris Elizabeth Philip
09-18-2024
Summary
Review ArticleNeonatal and maternal outcomes of mRNA versus Non-mRNA COVID-19 vaccines in pregnant patients: a systematic review and meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo69
09-18-2024- Juliana Almeida Oliveira ,
- Eloisa Gonçalves da Silva ,
- Ayse Filiz Gokmen Karasu ,
- Anelise Maria Nicolau Silva ,
- Chris Elizabeth Philip
Views222Abstract
Objective
To compare the effectiveness and safety of non-mRNA versus mRNA COVID-19 vaccines on pregnant women and their newborns in a systematic review with meta-analysis.
Data sources
We searched PubMed, Embase, and Cochrane Central in May 2023.
Study selection
The search strategy yielded 4451 results, 16 studies were fully reviewed. We selected case-control studies analysing non-mRNA versus mRNA vaccines. Data collection and analysis: we assessed the risk of bias using the Cochrane Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool. Standardised mean differences were pooled using random-effect models.
Data synthesis
We identified 8 prospective and retrospective studies with a total of 32,153 patients. Non-mRNA vaccines were associated with a higher incidence of fever (OR 2.67; 95% CI 2.08-3.43; p<0.001), and a lower incidence of fetal or neonatal death (OR 0.16; 95% CI 0.08-0.33; p<0.001). In subgroup analyses, the Jansen vaccine (Ad26.COV2.S) was found to have a higher rate of premature labor/delivery (OR 4.48; 95% CI 1.45-13.83; p=0.009) and missed/spontaneous abortion (OR 1.90; 95% CI 1.09-3.30; p=0.02), as compared with the Pfizer (BNT162b2) vaccine.
Conclusion
non-mRNA vaccines are associated with a lower incidence of fetal or neonatal death among pregnant women who receive a Covid19 vaccine, although at an increased rate of pyrexia compared with mRNA vaccines. Other studies are required for better assessment.
PROSPERO
CRD42023421814
Key-words coronavirus infectionsCOVID-19COVID-19 vaccinesInfant, newbornmRNA vaccinesPregnancy complicationsPregnant womenSARS-CoV-2See moreViews222
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleNeonatal and maternal outcomes of mRNA versus Non-mRNA COVID-19 vaccines in pregnant patients: a systematic review and meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo69
09-18-2024- Juliana Almeida Oliveira ,
- Eloisa Gonçalves da Silva ,
- Ayse Filiz Gokmen Karasu ,
- Anelise Maria Nicolau Silva ,
- Chris Elizabeth Philip
Views222Abstract
Objective
To compare the effectiveness and safety of non-mRNA versus mRNA COVID-19 vaccines on pregnant women and their newborns in a systematic review with meta-analysis.
Data sources
We searched PubMed, Embase, and Cochrane Central in May 2023.
Study selection
The search strategy yielded 4451 results, 16 studies were fully reviewed. We selected case-control studies analysing non-mRNA versus mRNA vaccines. Data collection and analysis: we assessed the risk of bias using the Cochrane Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool. Standardised mean differences were pooled using random-effect models.
Data synthesis
We identified 8 prospective and retrospective studies with a total of 32,153 patients. Non-mRNA vaccines were associated with a higher incidence of fever (OR 2.67; 95% CI 2.08-3.43; p<0.001), and a lower incidence of fetal or neonatal death (OR 0.16; 95% CI 0.08-0.33; p<0.001). In subgroup analyses, the Jansen vaccine (Ad26.COV2.S) was found to have a higher rate of premature labor/delivery (OR 4.48; 95% CI 1.45-13.83; p=0.009) and missed/spontaneous abortion (OR 1.90; 95% CI 1.09-3.30; p=0.02), as compared with the Pfizer (BNT162b2) vaccine.
Conclusion
non-mRNA vaccines are associated with a lower incidence of fetal or neonatal death among pregnant women who receive a Covid19 vaccine, although at an increased rate of pyrexia compared with mRNA vaccines. Other studies are required for better assessment.
PROSPERO
CRD42023421814
Key-words coronavirus infectionsCOVID-19COVID-19 vaccinesInfant, newbornmRNA vaccinesPregnancy complicationsPregnant womenSARS-CoV-2See moreThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Juliana Almeida Oliveira
-
Review Article
Immunosuppressants in women with repeated implantation failure in assisted reproductive techniques: a systematic review and meta-analysis
- Ana Clara Felix de Farias Santos ,
- Fernanda Valeriano Zamora ,
- Lubna Al-Sharif ,
- Kush Sehgal ,
- Deyvid Vieira Silva Cavalcante , [ ... ],
- Pedro Henrique Costa Matos da Silva
09-18-2024
Summary
Review ArticleImmunosuppressants in women with repeated implantation failure in assisted reproductive techniques: a systematic review and meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo70
09-18-2024- Ana Clara Felix de Farias Santos ,
- Fernanda Valeriano Zamora ,
- Lubna Al-Sharif ,
- Kush Sehgal ,
- Deyvid Vieira Silva Cavalcante ,
- Sarah Hasimyan Ferreira ,
- Pedro Henrique Costa Matos da Silva
Views204Abstract
Objective
To compare outcomes in patients with repeated implantation failure undergoing Intracytoplasmic Sperm Injection/In vitro fertilization (IVF/ICSI) plus immunosuppressants such as prednisolone, prednisone, or cyclosporine A versus the use of IVF/ICSI alone.
Data source
Databases were systematically searched in PubMed, Cochrane, and Embase databases in September 2023.
Study Selection
Randomized clinical trials and observational studies with the outcomes of interest were included.
Data collect
We computed odds ratios (ORs) for binary endpoints, with 95% confidence intervals (CIs). Heterogeneity was assessed using I2 statistics. Data were analyzed using Review Manager 5.4.The main outcomes were live birth, miscarriage, implantation rate, clinical pregnancy, and biochemical pregnancy.
Data synthesis
Seven studies with 2,829 patients were included. Immunosuppressive treatments were used in 1,312 (46.37%). Cyclosporine A improved implantation rate (OR 1.48; 95% CI 1.01-2.18) and clinical pregnancy (1.89, 95% CI 1.14-3.14). Compared to non-immunosuppressive treatment, prednisolone and prednisone did not improve live birth (OR 1.13, 95% CI 0.88-1.46) and miscarriage (OR 1.49, 95% CI 1.07-2.09). Prednisolone showed no significant effect in patients undergoing IVF/ICSI, clinical pregnancy (OR 1.34; 95% CI 0.76-2.36), or implantation rate (OR 1.36; 95% CI 0.76-2.42).
Conclusion
Cyclosporine A may promote implantation and clinical pregnancy rates. However, given the limited sample size, it is important to approach these findings with caution. Our results indicate that prednisolone and prednisone do not have any beneficial effects on clinical outcomes of IVF/ICSI patients with repeated implantation failure.
PROSPERO
CRD42023449655
Key-words Cyclosporine APrednisolone Immunosupressive agentsPrednisoneRepeated implantation failureReproductionReproductive techniques, assistedSee moreViews204This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleImmunosuppressants in women with repeated implantation failure in assisted reproductive techniques: a systematic review and meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo70
09-18-2024- Ana Clara Felix de Farias Santos ,
- Fernanda Valeriano Zamora ,
- Lubna Al-Sharif ,
- Kush Sehgal ,
- Deyvid Vieira Silva Cavalcante ,
- Sarah Hasimyan Ferreira ,
- Pedro Henrique Costa Matos da Silva
Views204Abstract
Objective
To compare outcomes in patients with repeated implantation failure undergoing Intracytoplasmic Sperm Injection/In vitro fertilization (IVF/ICSI) plus immunosuppressants such as prednisolone, prednisone, or cyclosporine A versus the use of IVF/ICSI alone.
Data source
Databases were systematically searched in PubMed, Cochrane, and Embase databases in September 2023.
Study Selection
Randomized clinical trials and observational studies with the outcomes of interest were included.
Data collect
We computed odds ratios (ORs) for binary endpoints, with 95% confidence intervals (CIs). Heterogeneity was assessed using I2 statistics. Data were analyzed using Review Manager 5.4.The main outcomes were live birth, miscarriage, implantation rate, clinical pregnancy, and biochemical pregnancy.
Data synthesis
Seven studies with 2,829 patients were included. Immunosuppressive treatments were used in 1,312 (46.37%). Cyclosporine A improved implantation rate (OR 1.48; 95% CI 1.01-2.18) and clinical pregnancy (1.89, 95% CI 1.14-3.14). Compared to non-immunosuppressive treatment, prednisolone and prednisone did not improve live birth (OR 1.13, 95% CI 0.88-1.46) and miscarriage (OR 1.49, 95% CI 1.07-2.09). Prednisolone showed no significant effect in patients undergoing IVF/ICSI, clinical pregnancy (OR 1.34; 95% CI 0.76-2.36), or implantation rate (OR 1.36; 95% CI 0.76-2.42).
Conclusion
Cyclosporine A may promote implantation and clinical pregnancy rates. However, given the limited sample size, it is important to approach these findings with caution. Our results indicate that prednisolone and prednisone do not have any beneficial effects on clinical outcomes of IVF/ICSI patients with repeated implantation failure.
PROSPERO
CRD42023449655
Key-words Cyclosporine APrednisolone Immunosupressive agentsPrednisoneRepeated implantation failureReproductionReproductive techniques, assistedSee moreThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Ana Clara Felix de Farias Santos
-
Review Article
Relationship between early age at menarche, older age at menopause and subtypes of breast cancer: a scoping review
- Lucas Casagrande Passoni Lopes ,
- Gabriel Araújo Medeiros ,
- Igor José Nogueira Gualberto ,
- Thales Baptista Gut ,
- Rafael Vasconcelos Silva Ferrazini , [ ... ],
- Carlos Antonio Negrato
09-06-2024
Summary
Review ArticleRelationship between early age at menarche, older age at menopause and subtypes of breast cancer: a scoping review
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo50
09-06-2024- Lucas Casagrande Passoni Lopes ,
- Gabriel Araújo Medeiros ,
- Igor José Nogueira Gualberto ,
- Thales Baptista Gut ,
- Rafael Vasconcelos Silva Ferrazini ,
- Carlos Antonio Negrato
Views170See moreAbstract
Objective
To determine the relationship between early age at menarche, late age at menopause with specific subtypes of breast cancer (BC).
Methods
A literature search was conducted in Embase, Lilacs, PubMed, Scopus, and Scielo databases, following the Joanna Briggs Institute scoping review protocol and answering the question “How early age at menarche or late age at menopause are related to different breast cancer subtypes?”.
Results
A number of 4,003 studies were identified, of which 17 were selected. Most of the included articles found a clear relationship between early menarche, late menopause and some subtypes of BC, mainly, PR+, ER+, luminal, and HER-2 tumors. However, some studies have found a contradictory relationship and one study didn’t find any relationship between them.
Conclusion
A relationship between early age at menarche and advanced age at menopause was observed with some subtypes of breast cancer, since other factors must be considered in its understanding.
Views170This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleRelationship between early age at menarche, older age at menopause and subtypes of breast cancer: a scoping review
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo50
09-06-2024- Lucas Casagrande Passoni Lopes ,
- Gabriel Araújo Medeiros ,
- Igor José Nogueira Gualberto ,
- Thales Baptista Gut ,
- Rafael Vasconcelos Silva Ferrazini ,
- Carlos Antonio Negrato
Views170See moreAbstract
Objective
To determine the relationship between early age at menarche, late age at menopause with specific subtypes of breast cancer (BC).
Methods
A literature search was conducted in Embase, Lilacs, PubMed, Scopus, and Scielo databases, following the Joanna Briggs Institute scoping review protocol and answering the question “How early age at menarche or late age at menopause are related to different breast cancer subtypes?”.
Results
A number of 4,003 studies were identified, of which 17 were selected. Most of the included articles found a clear relationship between early menarche, late menopause and some subtypes of BC, mainly, PR+, ER+, luminal, and HER-2 tumors. However, some studies have found a contradictory relationship and one study didn’t find any relationship between them.
Conclusion
A relationship between early age at menarche and advanced age at menopause was observed with some subtypes of breast cancer, since other factors must be considered in its understanding.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Lucas Casagrande Passoni Lopes
-
Review Article
Biochemical markers for prediction of the first half pregnancy losses: a review
- Meruyet Kuspanova ,
- Andrey Gaiday ,
- Nurzhamal Dzhardemaliyeva ,
- Maxat Tuganbayev ,
- Maksym Gorobeiko , [ ... ],
- Akylbek Tussupkaliyev
09-06-2024
Summary
Review ArticleBiochemical markers for prediction of the first half pregnancy losses: a review
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo72
09-06-2024- Meruyet Kuspanova ,
- Andrey Gaiday ,
- Nurzhamal Dzhardemaliyeva ,
- Maxat Tuganbayev ,
- Maksym Gorobeiko ,
- Andrii Dinets ,
- Saule Bermagambetova ,
- Zhanna Amirbekova ,
- Gulshat Oraltayeva ,
- Dinara Omertayeva ,
- Akylbek Tussupkaliyev
Views177Abstract
Objective
26% of all pregnancies end in miscarriage, and up to 10% of clinically diagnosed pregnancies, and recurrent pregnancy loss is 5% among couples of childbearing ages. Although there are several known causes of pregnancy loss in the first half, including recurrent pregnancy loss, including parental chromosomal abnormalities, uterine malformations, endocrinological disorders, and immunological abnormalities, about half of the cases of pregnancy loss in its first half remain unexplained.
Methods
The review includes observational controlled studies (case-control or cohort, longitudinal studies, reviews, meta-analyses), which include the study of biochemical factors for predicting pregnancy losses in the first half, in singlet pregnancy. The Newcastle-Ottawa Scale (NOS) was used to assess the research quality.
Results
Finally, 27 studies were included in the review, which has 134904 examined patients. The results of the review include estimates of β-human chorionic gonadotropin, progesterone, pregnancy-associated protein – A, angiogenic vascular factors, estradiol, α-fetoprotein, homocysteine and CA-125 as a predictors or markers of the first half pregnancy losses.
Conclusion
It may be concluded that to date, research data indicate the unavailability of any reliable biochemical marker for predicting pregnancy losses in its first half and require either a combination of them or comparison with clinical evidence. A fairly new model shall be considered for the assessment of α-fetoprotein in vaginal blood, which may have great prospects in predicting spontaneous miscarriages.
Key-words Biochemical markerLaboratory markerMiscarriagemissed abortionpredictionPregnancySpontaneous abortionSee moreViews177This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleBiochemical markers for prediction of the first half pregnancy losses: a review
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo72
09-06-2024- Meruyet Kuspanova ,
- Andrey Gaiday ,
- Nurzhamal Dzhardemaliyeva ,
- Maxat Tuganbayev ,
- Maksym Gorobeiko ,
- Andrii Dinets ,
- Saule Bermagambetova ,
- Zhanna Amirbekova ,
- Gulshat Oraltayeva ,
- Dinara Omertayeva ,
- Akylbek Tussupkaliyev
Views177Abstract
Objective
26% of all pregnancies end in miscarriage, and up to 10% of clinically diagnosed pregnancies, and recurrent pregnancy loss is 5% among couples of childbearing ages. Although there are several known causes of pregnancy loss in the first half, including recurrent pregnancy loss, including parental chromosomal abnormalities, uterine malformations, endocrinological disorders, and immunological abnormalities, about half of the cases of pregnancy loss in its first half remain unexplained.
Methods
The review includes observational controlled studies (case-control or cohort, longitudinal studies, reviews, meta-analyses), which include the study of biochemical factors for predicting pregnancy losses in the first half, in singlet pregnancy. The Newcastle-Ottawa Scale (NOS) was used to assess the research quality.
Results
Finally, 27 studies were included in the review, which has 134904 examined patients. The results of the review include estimates of β-human chorionic gonadotropin, progesterone, pregnancy-associated protein – A, angiogenic vascular factors, estradiol, α-fetoprotein, homocysteine and CA-125 as a predictors or markers of the first half pregnancy losses.
Conclusion
It may be concluded that to date, research data indicate the unavailability of any reliable biochemical marker for predicting pregnancy losses in its first half and require either a combination of them or comparison with clinical evidence. A fairly new model shall be considered for the assessment of α-fetoprotein in vaginal blood, which may have great prospects in predicting spontaneous miscarriages.
Key-words Biochemical markerLaboratory markerMiscarriagemissed abortionpredictionPregnancySpontaneous abortionSee moreThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Meruyet Kuspanova
-
Review Article
Artificial intelligence in mammography: a systematic review of the external validation
- Paulo Eduardo Souza Castelo Branco ,
- Adriane Helena Silva Franco ,
- Amanda Prates de Oliveira ,
- Isabela Maurício Costa Carneiro ,
- Luciana Maurício Costa de Carvalho , [ ... ],
- Eduardo Batista Cândido
09-04-2024
Summary
Review ArticleArtificial intelligence in mammography: a systematic review of the external validation
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo71
09-04-2024- Paulo Eduardo Souza Castelo Branco ,
- Adriane Helena Silva Franco ,
- Amanda Prates de Oliveira ,
- Isabela Maurício Costa Carneiro ,
- Luciana Maurício Costa de Carvalho ,
- Jonathan Igor Nunes de Souza ,
- Danniel Rodrigo Leandro ,
- Eduardo Batista Cândido
Views216See moreAbstract
Objective
To conduct a systematic review of external validation studies on the use of different Artificial Intelligence algorithms in breast cancer screening with mammography.
Data source
Our systematic review was conducted and reported following the PRISMA statement, using the PubMed, EMBASE, and Cochrane databases with the search terms “Artificial Intelligence,” “Mammography,” and their respective MeSH terms. We filtered publications from the past ten years (2014 – 2024) and in English.
Study selection
A total of 1,878 articles were found in the databases used in the research. After removing duplicates (373) and excluding those that did not address our PICO question (1,475), 30 studies were included in this work.
Data collection
The data from the studies were collected independently by five authors, and it was subsequently synthesized based on sample data, location, year, and their main results in terms of AUC, sensitivity, and specificity.
Data synthesis
It was demonstrated that the Area Under the ROC Curve (AUC) and sensitivity were similar to those of radiologists when using independent Artificial Intelligence. When used in conjunction with radiologists, statistically higher accuracy in mammogram evaluation was reported compared to the assessment by radiologists alone.
Conclusion
AI algorithms have emerged as a means to complement and enhance the performance and accuracy of radiologists. They also assist less experienced professionals in detecting possible lesions. Furthermore, this tool can be used to complement and improve the analyses conducted by medical professionals.
Views216This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleArtificial intelligence in mammography: a systematic review of the external validation
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo71
09-04-2024- Paulo Eduardo Souza Castelo Branco ,
- Adriane Helena Silva Franco ,
- Amanda Prates de Oliveira ,
- Isabela Maurício Costa Carneiro ,
- Luciana Maurício Costa de Carvalho ,
- Jonathan Igor Nunes de Souza ,
- Danniel Rodrigo Leandro ,
- Eduardo Batista Cândido
Views216See moreAbstract
Objective
To conduct a systematic review of external validation studies on the use of different Artificial Intelligence algorithms in breast cancer screening with mammography.
Data source
Our systematic review was conducted and reported following the PRISMA statement, using the PubMed, EMBASE, and Cochrane databases with the search terms “Artificial Intelligence,” “Mammography,” and their respective MeSH terms. We filtered publications from the past ten years (2014 – 2024) and in English.
Study selection
A total of 1,878 articles were found in the databases used in the research. After removing duplicates (373) and excluding those that did not address our PICO question (1,475), 30 studies were included in this work.
Data collection
The data from the studies were collected independently by five authors, and it was subsequently synthesized based on sample data, location, year, and their main results in terms of AUC, sensitivity, and specificity.
Data synthesis
It was demonstrated that the Area Under the ROC Curve (AUC) and sensitivity were similar to those of radiologists when using independent Artificial Intelligence. When used in conjunction with radiologists, statistically higher accuracy in mammogram evaluation was reported compared to the assessment by radiologists alone.
Conclusion
AI algorithms have emerged as a means to complement and enhance the performance and accuracy of radiologists. They also assist less experienced professionals in detecting possible lesions. Furthermore, this tool can be used to complement and improve the analyses conducted by medical professionals.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Paulo Eduardo Souza Castelo Branco
-
Review Article
HPV and coronary diseases in menopausal women: an integrative review
- Andrea de Neiva Granja ,
- Andressa Bianca Reis Lima ,
- Paulo Victor Brito Martins ,
- Bernardete Jorge Leal Salgado ,
- Rui Miguel Gil da Costa , [ ... ],
- Natalino Salgado Filho
07-26-2024
Summary
Review ArticleHPV and coronary diseases in menopausal women: an integrative review
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo57
07-26-2024- Andrea de Neiva Granja ,
- Andressa Bianca Reis Lima ,
- Paulo Victor Brito Martins ,
- Bernardete Jorge Leal Salgado ,
- Rui Miguel Gil da Costa ,
- Haissa Oliveira Brito ,
- Natalino Salgado Filho
Views159See moreAbstract
High-risk human papillomavirus (HPV) infection is associated with cervical cancer while low-risk HPV strains mostly cause benign lesions. Multiple studies have also associated HPV with coronary artery (CAD) disease in women. Furthermore, the climacteric period in women, triggers chronic inflammation and has major implications for CAD and associated lipid disorders. The association of HPV with coronary artery disease in climacteric women has few studies, and the objective of this review is to gather and analyse scientific data on the subject. This is an integrative review performed on PubMed and Google Scholar using the keywords “HPV”, “coronary heart disease” and “climacteric”, among these keywords the boolean operator AND and the publication date filter. (2018 onwards). Five articles were found, whose main results show presence of high-risk vaginal HPV in climacteric women. Climacterium and HPV were associated with a three-fold increased risk of CAD, as well as with factors related to menopause that promote atheroma formation, lipid disorders and chronic inflammation. Thus, these results support the association between HPV infection and CAD in climacteric women, possibly via chronic inflammation, hormonal factors related to menopause and dyslipidemia.
Views159This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleHPV and coronary diseases in menopausal women: an integrative review
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo57
07-26-2024- Andrea de Neiva Granja ,
- Andressa Bianca Reis Lima ,
- Paulo Victor Brito Martins ,
- Bernardete Jorge Leal Salgado ,
- Rui Miguel Gil da Costa ,
- Haissa Oliveira Brito ,
- Natalino Salgado Filho
Views159See moreAbstract
High-risk human papillomavirus (HPV) infection is associated with cervical cancer while low-risk HPV strains mostly cause benign lesions. Multiple studies have also associated HPV with coronary artery (CAD) disease in women. Furthermore, the climacteric period in women, triggers chronic inflammation and has major implications for CAD and associated lipid disorders. The association of HPV with coronary artery disease in climacteric women has few studies, and the objective of this review is to gather and analyse scientific data on the subject. This is an integrative review performed on PubMed and Google Scholar using the keywords “HPV”, “coronary heart disease” and “climacteric”, among these keywords the boolean operator AND and the publication date filter. (2018 onwards). Five articles were found, whose main results show presence of high-risk vaginal HPV in climacteric women. Climacterium and HPV were associated with a three-fold increased risk of CAD, as well as with factors related to menopause that promote atheroma formation, lipid disorders and chronic inflammation. Thus, these results support the association between HPV infection and CAD in climacteric women, possibly via chronic inflammation, hormonal factors related to menopause and dyslipidemia.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Andrea de Neiva Granja
-
Review Article
The use of phosphodiesterase inhibitors in the treatment of female sexual dysfunction: scoping review
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo49
07-26-2024
Summary
Review ArticleThe use of phosphodiesterase inhibitors in the treatment of female sexual dysfunction: scoping review
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo49
07-26-2024Views107See moreAbstract
Objective
The purpose of this study was to analyze the available evidence regarding the efficacy of iPDE5 in the treatment of female sexual dysfunction (FSD).
Methods
A comprehensive literature search was conducted in March 2023 through the main scientific databases.
Results
A total of 53 articles were identified, out of which, 6 met the predefined inclusion criteria. All of these were randomized controlled trials. Among the included studies, 4 demonstrated the effectiveness of sildenafil in improving sexual response and addressing FSD, while 2 studies failed to establish its efficacy in this context.
Conclusion
Overall, the efficacy of sildenafil in the treatment of FSD remains controversial and inconclusive based on the available evidence. Further research is necessary to clarify the therapeutic potential of iPDE5 in addressing FSD and to better understand the factors that influence treatment outcomes.
Views107This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleThe use of phosphodiesterase inhibitors in the treatment of female sexual dysfunction: scoping review
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo49
07-26-2024Views107See moreAbstract
Objective
The purpose of this study was to analyze the available evidence regarding the efficacy of iPDE5 in the treatment of female sexual dysfunction (FSD).
Methods
A comprehensive literature search was conducted in March 2023 through the main scientific databases.
Results
A total of 53 articles were identified, out of which, 6 met the predefined inclusion criteria. All of these were randomized controlled trials. Among the included studies, 4 demonstrated the effectiveness of sildenafil in improving sexual response and addressing FSD, while 2 studies failed to establish its efficacy in this context.
Conclusion
Overall, the efficacy of sildenafil in the treatment of FSD remains controversial and inconclusive based on the available evidence. Further research is necessary to clarify the therapeutic potential of iPDE5 in addressing FSD and to better understand the factors that influence treatment outcomes.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. -
Review Article
Effects of vitamin D supplementation on oxidative stress biomarkers of Iranian women with polycystic ovary syndrome: a meta-analysis study
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo37
06-27-2024
Summary
Review ArticleEffects of vitamin D supplementation on oxidative stress biomarkers of Iranian women with polycystic ovary syndrome: a meta-analysis study
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo37
06-27-2024Views203Abstract
Objective
To identify the impact of redox imbalance on the clinical evolution of patients with polycystic ovary syndrome and carry out a qualitative and quantitative projection of the benefits of vitamin D supplementation.
Data sources
Combinations of the keywords polycystic ovary syndrome, vitamin D, oxidative stress, reactive oxygen species, antioxidant, and free radicals were used in PubMed, Cochrane Library, LILACS, EMBASE, and Web of Science databases. The last search was conducted on August 22, 2023.Selection of studies: Based on the inclusion and exclusion criteria, studies were selected considering a low risk of bias, published in the last 5 years in English, which investigated the effects of vitamin D supplementation in women with PCOS, focusing on oxidative stress markers. Of the 136 articles retrieved, 6 intervention studies (445 women) were included.
Data collection
The risk of bias in included studies was assessed using the Jadad scale, and analysis and visualization of continuous data were performed using Review Manager 5.4.1, summarized as standardized mean differences (SMD) with confidence intervals (CI) of 95%.
Data synthesis
Vitamin D effectively reduced malondialdehyde (P=0.002) and total testosterone (P=0.0004) levels and increased total antioxidant capacity levels (P=0.01). Although possible improvements in the modified Ferriman–Gallwey hirsutism score, levels of sex hormone-binding globulin, and free androgen index were identified and the results were not statistically significant.
Conclusion
Vitamin D is a promising alternative for the treatment of PCOS with a positive influence on the oxidative, metabolic, and endocrine disorders of this syndrome.
Key-words Antioxidant therapycholecalciferolHyperandrogenismOxidative stressPolycystic ovary syndromeSee moreViews203This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleEffects of vitamin D supplementation on oxidative stress biomarkers of Iranian women with polycystic ovary syndrome: a meta-analysis study
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo37
06-27-2024Views203Abstract
Objective
To identify the impact of redox imbalance on the clinical evolution of patients with polycystic ovary syndrome and carry out a qualitative and quantitative projection of the benefits of vitamin D supplementation.
Data sources
Combinations of the keywords polycystic ovary syndrome, vitamin D, oxidative stress, reactive oxygen species, antioxidant, and free radicals were used in PubMed, Cochrane Library, LILACS, EMBASE, and Web of Science databases. The last search was conducted on August 22, 2023.Selection of studies: Based on the inclusion and exclusion criteria, studies were selected considering a low risk of bias, published in the last 5 years in English, which investigated the effects of vitamin D supplementation in women with PCOS, focusing on oxidative stress markers. Of the 136 articles retrieved, 6 intervention studies (445 women) were included.
Data collection
The risk of bias in included studies was assessed using the Jadad scale, and analysis and visualization of continuous data were performed using Review Manager 5.4.1, summarized as standardized mean differences (SMD) with confidence intervals (CI) of 95%.
Data synthesis
Vitamin D effectively reduced malondialdehyde (P=0.002) and total testosterone (P=0.0004) levels and increased total antioxidant capacity levels (P=0.01). Although possible improvements in the modified Ferriman–Gallwey hirsutism score, levels of sex hormone-binding globulin, and free androgen index were identified and the results were not statistically significant.
Conclusion
Vitamin D is a promising alternative for the treatment of PCOS with a positive influence on the oxidative, metabolic, and endocrine disorders of this syndrome.
Key-words Antioxidant therapycholecalciferolHyperandrogenismOxidative stressPolycystic ovary syndromeSee moreThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review Article Archives - Page 7 of 16 - Revista Brasileira de Ginecologia e Obstetrícia
